# Antineoplastic Activity of Methyl rosmarinate in Glioblastoma Cells

## TL;DR

Methyl rosmarinate, a plant-derived compound, shows anti-cancer effects in glioblastoma cells and interacts differently with a common chemotherapy drug.

## Contribution

The study reveals Methyl rosmarinate's anti-glioma activity and its variable synergy or antagonism with temozolomide in different cell lines.

## Key findings

- Methyl rosmarinate significantly reduced cell viability in U87 and T98 glioblastoma cells.
- The compound induced cell death by disrupting cell cycle checkpoints and inhibited cell migration.
- It showed synergy with temozolomide in U87 cells but antagonism in T98 cells.

## Abstract

Glioblastoma (GMB) is a remarkably aggressive brain malignancy characterized by high mortality rates, despite continuous advances in therapeutic approaches. Compounds derived from plants are being studied for their potent medicinal properties in the quest for more efficient therapies. This study investigated the anti-glioma properties of Methyl rosmarinate, a hydroxycinnamic acid isolated from Thymus thracicus Velen, which has previously demonstrated anti-cancer activity in various cell lines. Human glioblastoma cell lines U87 and T98 were treated with Methyl rosmarinate to assess its effect on cell viability, cell cycle distribution and migratory capacity using Trypan blue assay, flow cytometry and scratch wound healing assay, respectively. The combinatorial effects of Methyl rosmarinate and temozolomide were also analyzed with CompoSyn software. According to the outcomes, Methyl rosmarinate significantly reduced cell viability, induced cell death by interfering in cell cycle checkpoints, and inhibited migration in both GMB cell lines. Notably, in U87 cells, the compound showed a synergistic impact with temozolomide, whereas in T98 cells, there was an antagonistic relationship. These results suggest that Methyl rosmarinate has potential anti-glioma properties; however, more in vivo research is needed.